We came across a bullish thesis on Arrowhead Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on ARWR. Arrowhead Pharmaceuticals, Inc.’s share was trading at $66.25 as of January 15th. ARWR’s trailing and forward P/E were 478.56 and 111.11 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Arrowhead Pharmaceuticals is emerging as a leading RNAi-focused biotechnology company, anchored by its flagship...
